Cargando…

Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer

BACKGROUD: As magicians of the DNA world, topoisomerases resolve all of the topological problems in relation to DNA during a variety of genetic processes. While the prognostic value of topoisomerase isoenzymes in epithelial ovarian carcinoma (EOC) is still elusive. In current study, we investigated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Yang, Li, Liang-Dong, Li, Jun, Lu, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912764/ https://www.ncbi.nlm.nih.gov/pubmed/27315793 http://dx.doi.org/10.1186/s13048-016-0244-9

Ejemplares similares

Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer
por: Lee, Yu-Chieh, et al.
Publicado: (2015)

Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II
por: Xu, Huanli, et al.
Publicado: (2016)

DNA topoisomerases as molecular targets for anticancer drugs
por: Buzun, Kamila, et al.
Publicado: (2020)

Prognostic values of S100 family members in ovarian cancer patients
por: Bai, Yang, et al.
Publicado: (2018)

On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs
por: Wu, Chyuan-Chuan, et al.
Publicado: (2013)

Biomodulation by Hyperthermia of Topoisomerase II‐Targeting Drugs in Human Colorectal Cancer Cells
por: Hirohashi, Yoshimi, et al.
Publicado: (1995)

Big data-based identification of methylated genes associated with drug resistance and prognosis in ovarian cancer
por: Yan, Bingbing, et al.
Publicado: (2020)

Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II
por: Lee, Ka C., et al.
Publicado: (2016)

Topoisomerase I expression is associated with prognosis in postoperative non‐small cell lung cancer patients
por: Lu, Baohua, et al.
Publicado: (2016)

Recent developments in topoisomerase-targeted cancer chemotherapy
por: Hevener, KirkE., et al.
Publicado: (2018)

Prognostic role of topoisomerase-IIα in advanced ovarian cancer patients
por: Ferrandina, G, et al.
Publicado: (2008)

DNA topoisomerase IIα and -β expression in human ovarian cancer
por: Withoff, S, et al.
Publicado: (1999)

Altered Expression of γ‐Glutamylcysteine Synthetase, Metallothionein and Topoisomerase I or II during Acquisition of Drug Resistance to Cisplatin in Human Ovarian Cancer Cells
por: Kikuchi, Yoshihiro, et al.
Publicado: (1997)

Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer
por: Yang, Fengmei, et al.
Publicado: (2018)

Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan–Meier plotter
por: Hou, Guo-Xin, et al.
Publicado: (2017)

Targeting Nrf2 may reverse the drug resistance in ovarian cancer
por: Li, Danjie, et al.
Publicado: (2021)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

Overexpression of PDK4 is associated with cell proliferation, drug resistance and poor prognosis in ovarian cancer
por: Wang, Jinghao, et al.
Publicado: (2018)

The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religation
por: Zhao, Wuli, et al.
Publicado: (2015)

Effects of DNA topoisomerase IIα splice variants on acquired drug resistance
por: Elton, Terry S., et al.
Publicado: (2020)

Targeting DNA topoisomerases: past & future
por: Gmeiner, William H., et al.
Publicado: (2021)

Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors
por: Madkour, Moustafa M., et al.
Publicado: (2023)

Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets
por: Alatise, Kharimat Lora, et al.
Publicado: (2022)

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
por: Wray, Justin, et al.
Publicado: (2009)

Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
por: McFadden, Melayshia, et al.
Publicado: (2021)

The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer
por: Li, Jun, et al.
Publicado: (2017)

Topoisomerase IIβ mediates the resistance of glioblastoma stem cells to replication stress-inducing drugs
por: Kenig, Saša, et al.
Publicado: (2016)

A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer
por: Xu, Xue-Lian, et al.
Publicado: (2016)

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets
por: Gilbert, D C, et al.
Publicado: (2012)

Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer
por: Feng, Li-yuan, et al.
Publicado: (2020)

New Topoisomerase I mutations are associated with resistance to camptothecin
por: Gongora, Céline, et al.
Publicado: (2011)

CK2-Mediated Hyperphosphorylation of Topoisomerase I Targets Serine 506, Enhances Topoisomerase I–DNA Binding, and Increases Cellular Camptothecin Sensitivity
por: Bandyopadhyay, Keya, et al.
Publicado: (2012)

Co-Delivery of Curcumin and Paclitaxel by “Core-Shell” Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer
por: Zhao, Meng-Dan, et al.
Publicado: (2019)

Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance
por: Lage, H, et al.
Publicado: (2000)

The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance
por: Lotz, Christophe, et al.
Publicado: (2020)

In Vitro and In Silico Mechanistic Insights into miR-21-5p-Mediated Topoisomerase Drug Resistance in Human Colorectal Cancer Cells
por: Chen, Jung-Chien, et al.
Publicado: (2019)

Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer
por: Flörkemeier, Inken, et al.
Publicado: (2021)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
por: Turner, Joel G., et al.
Publicado: (2016)

Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013)

Targeting DNA Topoisomerase II in Antifungal Chemotherapy
por: Kondaka, Kavya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jfm2n5125plvfo53bgk2r1a1ha